Detail akcie Klotho Neuros Rg online

Business Summary: Klotho Neurosciences, Inc. develops essential medicines for the treatment of chronic diseases such as cancer, cardiovascular, and neurodegenerative disorders. The Company's licensed platforms, namely, a generic drug portfolio and a biosimilar biologics platform uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Its primary focus is the advancement of a sustainable portfolio of cell and gene therapy product candidates for age-associated neurologic diseases, both rare orphan diseases and diseases in larger patient populations. The Company's two lead gene therapy product candidates are KLTO-101 (AAV9-CMV-sKL) for the treatment or prevention of Alzheimer’s disease, and KLTO-202 (AAVmyo-Des-sKL) gene therapy product for the treatment and prevention of Lou Gehrig’s disease (amyotrophic lateral sclerosis).
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Klotho Neurosciences Inc revenues was not reported. Net loss increased from $4.1M to $9.2M. Higher net loss reflects Interest expense increase from $60K to $3.5M (expense), Professional fees increase of 45% to $2.4M (expense), Change in fair value of warrant liabilit decrease from $1K (income) to $29K (expense). Basic Earnings per Share excluding Extraordinary Items remained flat at -$0.25.